<ul>
<li>如果你在想輝瑞是否正在悄然轉變為一個價值投資機會，而不僅僅是一個防禦性的醫療保健名稱，你並不孤單，最近的數據給我們提供了很多分析的空間。</li>
<li>儘管經歷了艱難的幾年，輝瑞的股價在三年內仍下跌約 42.8%，五年內下跌 13.4%，但它已經開始穩定。過去一週上漲了 0.4%，過去一個月上漲了 1.1%，過去一年上漲了 9.1%，儘管年初至今仍下跌 3.0%。</li>
<li>最近的新聞集中在輝瑞重塑其疫情後的身份。公司在非 COVID 產品線方面進行了大量投資，並追求戰略交易和合作夥伴關係，以多樣化未來的收入。同時，投資者正在權衡關於專利懸崖、藥品定價改革以及新療法替代成熟重磅藥物所需的漫長過程的持續討論。</li>
<li>在我們的估值框架中，輝瑞在低估檢查中得分為 5/6，給出了一個堅實的估值分數 5，這表明市場可能仍在低估故事的某些部分。接下來，我們將分析標準的估值方法，然後以更細緻的方式思考這隻股票的真實價值。</li>
</ul>
<p>瞭解為什麼輝瑞過去一年 9.1% 的回報落後於同行。</p>
<h3>方法 1：輝瑞折現現金流（DCF）分析</h3>
<p>折現現金流（DCF）模型通過預測未來現金流並將其折現回現在來估算公司的當前價值。對於輝瑞，該模型以過去 12 個月的自由現金流約 99 億美元為起點，然後結合分析師的預測和未來十年的長期外推。</p>
<p>分析師預計輝瑞將在未來幾年內將自由現金流提升至中等十幾億美元，預計到 2026 年約為 193 億美元，到 2035 年逐漸降至約 165 億美元，隨着增長的正常化。Simply Wall St 使用兩階段自由現金流到股權的框架，第一階段依賴於分析師的估計，第二階段假設增長放緩。</p>
<p>當這些未來現金流被折現回現值時，該模型得出的內在價值約為每股 62.40 美元。與當前市場價格相比，這意味着大約 58.7% 的折扣，表明市場價格顯著低於該模型對輝瑞現金生成潛力的估計。</p>
<p><strong>結果：被低估</strong></p>
<p>我們的折現現金流（DCF）分析表明輝瑞被低估了 58.7%。將其添加到你的觀察列表或投資組合中，或發現基於現金流的 904 只被低估股票。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1706" height="760" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf"/></p>
<p>截至 2025 年 12 月的輝瑞折現現金流</p>
<p>前往我們公司報告的估值部分，瞭解我們如何得出輝瑞的公允價值的更多細節。</p>
<h3>方法 2：輝瑞市盈率</h3>
<p>對於像輝瑞這樣成熟且盈利的企業，市盈率（PE）是衡量投資者是否為每一美元的收益支付合理價格的實用方法。一般來説，具有更強增長前景和較低感知風險的公司往往能獲得更高的市盈率，而增長緩慢或不確定性較高的公司通常會指向較低、更保守的倍數。</p>
<p>輝瑞目前的市盈率約為 15.0 倍，低於大約 19.9 倍的製藥行業整體平均水平，也低於約 17.5 倍的同行平均水平。從表面上看，這一折扣表明市場對輝瑞的收益軌跡和疫情後的重置仍持謹慎態度。</p>
<p>Simply Wall St 的公允比率框架進一步估算輝瑞應該交易的市盈率，考慮到其收益增長前景、利潤率、規模、行業特徵和風險因素。對於輝瑞，該公允比率為更高的 26.2 倍，這表明一旦考慮到這些基本面，股票似乎應當獲得比同行和整個行業更高的倍數。將公允比率與當前的 15.0 倍市盈率進行比較，突顯出這隻股票在這一基礎上看起來被低估。</p>
<p><strong>結果：被低估</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="650" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry"/></p>
<p>截至 2025 年 12 月的 NYSE:PFE 市盈率</p>
<p>市盈率講述了一個故事，但如果真正的機會在其他地方呢？發現 1447 家公司，內部人士正在大舉押注於爆炸性增長。</p>
<h3>提升你的決策能力：選擇你的輝瑞敍事</h3>
<p>早些時候我們提到，有一種更好的方式來理解估值，因此讓我們向你介紹敍事，這是一種將你對輝瑞未來的看法與收入、收益、利潤率和公允價值估計等具體數字聯繫起來的簡單方法。敍事是你假設背後的故事，將關於產品線、專利懸崖或成本削減的想法轉化為結構化的預測，然後轉化為公允價值，你可以直接與今天的股價進行比較，以決定是買入、持有還是賣出。在 Simply Wall St 上的敍事，面向數百萬投資者，通過社區頁面提供，旨在易於使用，並隨着新數據、新聞和收益的發佈動態更新，以便你的故事與現實保持同步。例如，一個輝瑞敍事可能假設基於更強的利潤率和成功的肥胖及腫瘤擴展，公允價值約為每股 35.77 美元，而一個更謹慎的敍事可能會看到公允價值接近 24.00 美元，反映出更嚴格的定價、較慢的增長和執行風險。</p>
<p>然而，對於輝瑞，我們將為你提供兩個領先輝瑞敍事的預覽：</p>
<p><strong>🐂 輝瑞牛市案例</strong></p>
<p>在這個看漲敍事中，公允價值估計為每股 29.08 美元。</p>
<p>在最後收盤價為 25.80 美元的情況下，這意味着輝瑞的交易價格大約低於該公允價值 11.3%。</p>
<p>在這種情況下，收入增長模型約為每年-2.9%。</p>
<ul>
<li>假設肥胖症、腫瘤學和其他晚期創新療法支持輝瑞的重新評級，並在專利到期的情況下支撐長期盈利韌性。</li>
<li>依靠數字化、新興市場擴張和有針對性的交易來推動利潤改善，並減少 COVID 時代的波動性。</li>
<li>與看漲分析師的觀點大致一致，他們認為美國整體定價擔憂的緩解和管道執行是多重擴張的催化劑。</li>
</ul>
<p><strong>🐻 輝瑞熊市案例</strong></p>
<p>在這個更謹慎的敍述中，公允價值定為每股 24.00 美元。</p>
<p>目前股價為 25.80 美元，這意味着輝瑞的交易價格約高出這一悲觀公允價值 7.5%。</p>
<p>在這種情況下，收入增長模型約為每年-4.2%。</p>
<ul>
<li>強調全球藥品價格壓力、美國政策改革和關鍵產品的專利懸崖是可能侵蝕收入和壓縮利潤的逆風。</li>
<li>質疑新的研發資產和收購是否能及時到位，並且規模足夠大，以抵消老牌暢銷藥的侵蝕。</li>
<li>認為今天的股價接近公允價值或略顯高估，如果定價改革和競爭壓力在悲觀預期下展開，潛在上行空間有限。</li>
</ul>
<p>你認為輝瑞的故事還有更多內容嗎？前往我們的社區看看其他人怎麼説！</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1510" height="1044" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price"/></p>
<p>紐約證券交易所:PFE 1 年股票價格走勢圖</p>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的，而是完全自主的塔樓，能夠在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

輝瑞

<p>輝瑞可能正在從防禦性股票轉變為疫情後價值投資機會。儘管過去股價下跌，但最近的漲幅和在非新冠領域的戰略投資表明公司正在重組。使用折現現金流（DCF）和市盈率（PE）進行的估值分析顯示，輝瑞被低估，與內在價值和行業平均水平相比存在顯著折扣</p>

<ul>
<li>If you are wondering whether Pfizer is quietly setting up to be a value play rather than just a defensive healthcare name, you are not alone, and the recent numbers give us plenty to unpack.</li>
<li>Despite a tough few years, with the stock still down about 42.8% over three years and 13.4% over five, it has started to stabilize. It has posted a modest 0.4% gain over the last week, 1.1% over the last month, and a 9.1% rise over the past year, even though it remains down 3.0% year to date.</li>
<li>Recent news has centered on Pfizer reshaping its post pandemic identity. The company has been investing heavily in its non COVID pipeline and pursuing strategic deals and partnerships to diversify future revenue. At the same time, investors are weighing ongoing debates around patent cliffs, drug pricing reforms, and the long runway needed for new therapies to replace maturing blockbusters.</li>
<li>On our valuation framework, Pfizer scores a 5/6 on undervaluation checks, giving it a solid valuation score of 5 that suggests the market may still be underestimating parts of the story. Next, we will unpack the standard valuation approaches before finishing with a more nuanced way to think about what this stock is really worth.</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你在想輝瑞是否正在悄然轉變為一個價值投資機會，而不僅僅是一個防禦性的醫療保健名稱，你並不孤單，最近的數據給我們提供了很多分析的空間。</li>
<li>儘管經歷了艱難的幾年，輝瑞的股價在三年內仍下跌約 42.8%，五年內下跌 13.4%，但它已經開始穩定。過去一週上漲了 0.4%，過去一個月上漲了 1.1%，過去一年上漲了 9.1%，儘管年初至今仍下跌 3.0%。</li>
<li>最近的新聞集中在輝瑞重塑其疫情後的身份。公司在非 COVID 產品線方面進行了大量投資，並追求戰略交易和合作夥伴關係，以多樣化未來的收入。同時，投資者正在權衡關於專利懸崖、藥品定價改革以及新療法替代成熟重磅藥物所需的漫長過程的持續討論。</li>
<li>在我們的估值框架中，輝瑞在低估檢查中得分為 5/6，給出了一個堅實的估值分數 5，這表明市場可能仍在低估故事的某些部分。接下來，我們將分析標準的估值方法，然後以更細緻的方式思考這隻股票的真實價值。</li>
</ul>
</div><p>Find out why Pfizer's 9.1% return over the last year is lagging behind its peers.</p>
<div class="lb-trans"><p>瞭解為什麼輝瑞過去一年 9.1% 的回報落後於同行。</p>
</div><h3>Approach 1: Pfizer Discounted Cash Flow (DCF) Analysis</h3>
<div class="lb-trans"><h3>方法 1：輝瑞折現現金流（DCF）分析</h3>
</div><p>A Discounted Cash Flow (DCF) model estimates what a company is worth today by projecting future cash flows and discounting them back to the present. For Pfizer, the model starts with last twelve month Free Cash Flow of about $9.9 billion, then layers in analyst forecasts and longer term extrapolations for the next decade.</p>
<div class="lb-trans"><p>折現現金流（DCF）模型通過預測未來現金流並將其折現回現在來估算公司的當前價值。對於輝瑞，該模型以過去 12 個月的自由現金流約 99 億美元為起點，然後結合分析師的預測和未來十年的長期外推。</p>
</div><p>Analysts expect Pfizer to lift Free Cash Flow into the mid teens over the coming years, with projections around $19.3 billion in 2026 and tapering toward roughly $16.5 billion by 2035 as growth normalizes. Simply Wall St uses a 2 Stage Free Cash Flow to Equity framework, where the first stage relies on analyst estimates and the second stage assumes more modest, slowing growth.</p>
<div class="lb-trans"><p>分析師預計輝瑞將在未來幾年內將自由現金流提升至中等十幾億美元，預計到 2026 年約為 193 億美元，到 2035 年逐漸降至約 165 億美元，隨着增長的正常化。Simply Wall St 使用兩階段自由現金流到股權的框架，第一階段依賴於分析師的估計，第二階段假設增長放緩。</p>
</div><p>When those future cash flows are discounted back, the model arrives at an intrinsic value of about $62.40 per share. Compared with the current market price, this implies roughly a 58.7% discount, indicating that the market price is significantly below this model’s estimate of Pfizer’s cash generation potential.</p>
<div class="lb-trans"><p>當這些未來現金流被折現回現值時，該模型得出的內在價值約為每股 62.40 美元。與當前市場價格相比，這意味着大約 58.7% 的折扣，表明市場價格顯著低於該模型對輝瑞現金生成潛力的估計。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>結果：被低估</strong></p>
</div><p>Our Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 58.7%. Track this in your watchlist or portfolio, or discover 904 more undervalued stocks based on cash flows.</p>
<div class="lb-trans"><p>我們的折現現金流（DCF）分析表明輝瑞被低估了 58.7%。將其添加到你的觀察列表或投資組合中，或發現基於現金流的 904 只被低估股票。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf" alt="" original-src="https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/dcf"/></p>
<p>PFE Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的輝瑞折現現金流</p>
</div><p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Pfizer.</p>
<div class="lb-trans"><p>前往我們公司報告的估值部分，瞭解我們如何得出輝瑞的公允價值的更多細節。</p>
</div><h3>Approach 2: Pfizer Price vs Earnings</h3>
<div class="lb-trans"><h3>方法 2：輝瑞市盈率</h3>
</div><p>For a mature, profitable business like Pfizer, the Price to Earnings, or PE, ratio is a practical way to gauge whether investors are paying a reasonable price for each dollar of earnings. In general, companies with stronger growth prospects and lower perceived risk tend to justify a higher PE, while slower growth or higher uncertainty usually points to a lower, more conservative multiple.</p>
<div class="lb-trans"><p>對於像輝瑞這樣成熟且盈利的企業，市盈率（PE）是衡量投資者是否為每一美元的收益支付合理價格的實用方法。一般來説，具有更強增長前景和較低感知風險的公司往往能獲得更高的市盈率，而增長緩慢或不確定性較高的公司通常會指向較低、更保守的倍數。</p>
</div><p>Pfizer currently trades on a PE of about 15.0x, which sits below the broader Pharmaceuticals industry average of roughly 19.9x and also below the peer group average of about 17.5x. On the surface, that discount suggests the market is still cautious about Pfizer’s earnings trajectory and post pandemic reset.</p>
<div class="lb-trans"><p>輝瑞目前的市盈率約為 15.0 倍，低於大約 19.9 倍的製藥行業整體平均水平，也低於約 17.5 倍的同行平均水平。從表面上看，這一折扣表明市場對輝瑞的收益軌跡和疫情後的重置仍持謹慎態度。</p>
</div><p>Simply Wall St’s Fair Ratio framework goes a step further by estimating what PE Pfizer should trade on, given its earnings growth outlook, profit margins, size, industry profile, and risk factors. For Pfizer, that Fair Ratio is a much higher 26.2x, which indicates that, once these fundamentals are accounted for, the shares appear to warrant a richer multiple than both peers and the sector overall. Comparing the Fair Ratio with the current 15.0x PE highlights a stock that looks undervalued on this basis.</p>
<div class="lb-trans"><p>Simply Wall St 的公允比率框架進一步估算輝瑞應該交易的市盈率，考慮到其收益增長前景、利潤率、規模、行業特徵和風險因素。對於輝瑞，該公允比率為更高的 26.2 倍，這表明一旦考慮到這些基本面，股票似乎應當獲得比同行和整個行業更高的倍數。將公允比率與當前的 15.0 倍市盈率進行比較，突顯出這隻股票在這一基礎上看起來被低估。</p>
</div><p><strong>Result: UNDERVALUED</strong></p>
<div class="lb-trans"><p><strong>結果：被低估</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/pe-multiple-vs-industry"/></p>
<p>NYSE:PFE PE Ratio as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 NYSE:PFE 市盈率</p>
</div><p>PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1447 companies where insiders are betting big on explosive growth.</p>
<div class="lb-trans"><p>市盈率講述了一個故事，但如果真正的機會在其他地方呢？發現 1447 家公司，內部人士正在大舉押注於爆炸性增長。</p>
</div><h3>Upgrade Your Decision Making: Choose your Pfizer Narrative</h3>
<div class="lb-trans"><h3>提升你的決策能力：選擇你的輝瑞敍事</h3>
</div><p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to connect your view of Pfizer’s future to concrete numbers like revenue, earnings, margins, and a fair value estimate. A Narrative is the story behind your assumptions, turning ideas about pipelines, patent cliffs, or cost cuts into a structured forecast, and then into a fair value that you can directly compare to today’s share price to inform a decision on whether to buy, hold, or sell. Narratives on Simply Wall St, available to millions of investors through the Community page, are designed to be easy to use, and they update dynamically as new data, news, and earnings are released so your story stays in sync with reality. For example, one Pfizer Narrative might assume a fair value of about $35.77 per share based on stronger margins and a successful obesity and oncology expansion, while a more cautious Narrative might see fair value closer to $24.00, reflecting tougher pricing, slower growth, and execution risks.</p>
<div class="lb-trans"><p>早些時候我們提到，有一種更好的方式來理解估值，因此讓我們向你介紹敍事，這是一種將你對輝瑞未來的看法與收入、收益、利潤率和公允價值估計等具體數字聯繫起來的簡單方法。敍事是你假設背後的故事，將關於產品線、專利懸崖或成本削減的想法轉化為結構化的預測，然後轉化為公允價值，你可以直接與今天的股價進行比較，以決定是買入、持有還是賣出。在 Simply Wall St 上的敍事，面向數百萬投資者，通過社區頁面提供，旨在易於使用，並隨着新數據、新聞和收益的發佈動態更新，以便你的故事與現實保持同步。例如，一個輝瑞敍事可能假設基於更強的利潤率和成功的肥胖及腫瘤擴展，公允價值約為每股 35.77 美元，而一個更謹慎的敍事可能會看到公允價值接近 24.00 美元，反映出更嚴格的定價、較慢的增長和執行風險。</p>
</div><p>For Pfizer however we will make it really easy for you with previews of two leading Pfizer Narratives:</p>
<div class="lb-trans"><p>然而，對於輝瑞，我們將為你提供兩個領先輝瑞敍事的預覽：</p>
</div><p><strong>🐂 Pfizer Bull Case</strong></p>
<div class="lb-trans"><p><strong>🐂 輝瑞牛市案例</strong></p>
</div><p>Fair value in this bullish Narrative is estimated at $29.08 per share.</p>
<div class="lb-trans"><p>在這個看漲敍事中，公允價值估計為每股 29.08 美元。</p>
</div><p>At the last close of $25.80, this implies Pfizer is trading at roughly 11.3% below that fair value.</p>
<div class="lb-trans"><p>在最後收盤價為 25.80 美元的情況下，這意味着輝瑞的交易價格大約低於該公允價值 11.3%。</p>
</div><p>Revenue growth in this scenario is modeled at approximately -2.9% a year.</p>
<div class="lb-trans"><p>在這種情況下，收入增長模型約為每年-2.9%。</p>
</div><ul>
<li>Assumes obesity, oncology, and other late stage innovative therapies support a rerating of Pfizer and underpin long term earnings resilience despite patent expirations.</li>
<li>Leans on digitalization, emerging market expansion, and targeted deals to drive margin improvement and diversify away from COVID era volatility.</li>
<li>Aligns broadly with bullish analysts who see sector wide easing of U.S. pricing fears and pipeline execution as catalysts for multiple expansion.</li>
</ul>
<div class="lb-trans"><ul>
<li>假設肥胖症、腫瘤學和其他晚期創新療法支持輝瑞的重新評級，並在專利到期的情況下支撐長期盈利韌性。</li>
<li>依靠數字化、新興市場擴張和有針對性的交易來推動利潤改善，並減少 COVID 時代的波動性。</li>
<li>與看漲分析師的觀點大致一致，他們認為美國整體定價擔憂的緩解和管道執行是多重擴張的催化劑。</li>
</ul>
</div><p><strong>🐻 Pfizer Bear Case</strong></p>
<div class="lb-trans"><p><strong>🐻 輝瑞熊市案例</strong></p>
</div><p>Fair value in this more cautious Narrative is set at $24.00 per share.</p>
<div class="lb-trans"><p>在這個更謹慎的敍述中，公允價值定為每股 24.00 美元。</p>
</div><p>With the stock at $25.80, that implies Pfizer is trading about 7.5% above this bearish fair value.</p>
<div class="lb-trans"><p>目前股價為 25.80 美元，這意味着輝瑞的交易價格約高出這一悲觀公允價值 7.5%。</p>
</div><p>Revenue growth in this scenario is modeled at around -4.2% a year.</p>
<div class="lb-trans"><p>在這種情況下，收入增長模型約為每年-4.2%。</p>
</div><ul>
<li>Emphasizes global drug price pressure, U.S. policy reforms, and patent cliffs on key products as headwinds that could erode revenue and compress margins.</li>
<li>Questions whether new R&amp;D assets and acquisitions can arrive fast enough, and at sufficient scale, to offset erosion from aging blockbusters.</li>
<li>Views today’s share price as close to fairly valued or slightly rich, with limited upside if pricing reforms and competitive pressures play out at the pessimistic end of expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li>強調全球藥品價格壓力、美國政策改革和關鍵產品的專利懸崖是可能侵蝕收入和壓縮利潤的逆風。</li>
<li>質疑新的研發資產和收購是否能及時到位，並且規模足夠大，以抵消老牌暢銷藥的侵蝕。</li>
<li>認為今天的股價接近公允價值或略顯高估，如果定價改革和競爭壓力在悲觀預期下展開，潛在上行空間有限。</li>
</ul>
</div><p>Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!</p>
<div class="lb-trans"><p>你認為輝瑞的故事還有更多內容嗎？前往我們的社區看看其他人怎麼説！</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price" alt="" original-src="https://images.simplywall.st/company/3b07801a-1c3a-46e6-a7ff-e1f59f31c466/chart/quote-price"/></p>
<p>NYSE:PFE 1-Year Stock Price Chart</p>
<div class="lb-trans"><p>紐約證券交易所:PFE 1 年股票價格走勢圖</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的，而是完全自主的塔樓，能夠在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring?

- 輝瑞公司股票在過去三年下跌約 42.8%，但近期開始穩定。  
- 該公司正在重塑疫情後的身份，投資非 COVID 產品線以多元化收入。  
- 估值分析顯示輝瑞股票被低估，當前市價顯著低於其現金生成潛力。  

輝瑞在疫情後重組後是否從防禦性股票轉變為價值投資機會？